Latest Imexhs (ASX:IME) News

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.

IMEXHS Limited reported a 12% rise in annual recurring revenue to $36.8 million in 1H FY26, powered by its AI-enabled radiology platform now live in a public hospital network. Underlying EBITDA surged 311% to $1.27 million despite ongoing sector liquidity challenges in Colombia.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

IMEXHS Limited has swung to a profit of $66,200 in 1H FY26, driven by a 17% revenue increase and a surge in underlying EBITDA to $1.27 million. The company’s AI-native radiology platform and Latin American partner expansion underpin growth amid ongoing sector liquidity challenges.

IMEXHS Limited posted a 21% revenue increase in Q2 FY26, driven by a landmark public tender in Mexico deploying its AI-powered Aquila+ radiology platform. The company’s proprietary AI agents are now operational in live environments, supporting its strategy to own the full radiology workflow.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

IMEXHS has landed a significant public tender in Mexico, deploying its AI-powered Aquila+ radiology platform across 20 hospitals, adding $384,000 in new annual recurring revenue and advancing its Latin American expansion.

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

IMEXHS Limited exceeded FY25 revenue and EBITDA guidance, driven by strategic contract wins and AI-powered workflow automation. The company projects stronger software growth and sustained profitability in FY26.

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

IMEXHS Limited kicked off FY26 with a 13% revenue increase and a strategic pivot to an AI-native radiology workflow platform, securing major contracts in Latin America and advancing proprietary AI agents.